6242.TWO Li Kang Biomedical Co Ltd
- Market cap
- TWD 1.00B
- P/E
- 13.2x
- P/B
- 1.21x
- ROE
- 8.4%
- Dividend yield
- 6.35%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6242.TWO undervalued?
Graham number6242.TWO trades 15.8% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Li Kang Biomedical Co Ltd fundamental analysis
No fundamental analysis for Li Kang Biomedical Co Ltd yet.
Li Kang Biomedical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. produces and sells pharmaceuticals, beauty products, and health food. It offers Chinese and Western medicines, nutritional supplements, beauty and skincare products, and daily necessities products. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.
Full company profileLi Kang Biomedical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Li Kang Biomedical Co Ltd annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 451M | 496M | 496M | 483M | 457M | 387M | 684M | 629M | 566M | 589M | 567M |
| Gross Profit | 304M | 338M | 339M | 333M | 301M | 265M | 389M | 426M | 386M | 398M | 380M |
| Operating Income | 66.6M | 84.7M | 91.0M | 88.3M | 87.5M | 63.9M | 141M | 140M | 90.0M | 98.3M | 79.7M |
| EBITDA | - | 157M | 115M | 110M | 103M | 76.8M | 152M | 152M | 112M | 113M | 93.6M |
| Net Income | 61.5M | 134M | 76.7M | 72.0M | 69.3M | 51.4M | 112M | 111M | 77.0M | 83.8M | 70.4M |
| EPS | - | 6.02 | 3.46 | 2.58 | 2.48 | 1.85 | 4.02 | 3.98 | 2.42 | 2.64 | 2.21 |
| Balance Sheet | |||||||||||
| Total Assets | 555M | 596M | 610M | 626M | 645M | 616M | 689M | 827M | 1.04B | 1.09B | 1.14B |
| Total Liabilities | 214M | 150M | 143M | 143M | 136M | 124M | 119M | 197M | 180M | 222M | 295M |
| Shareholders' Equity | 341M | 446M | 467M | 483M | 508M | 492M | 570M | 630M | 856M | 871M | 843M |
| Cash & Short-term Investments | 150M | 204M | 165M | 142M | 221M | 176M | 263M | 301M | 64.9M | 42.9M | 60.0M |
| Total Debt | - | - | - | - | 55.1M | 41.3M | 18.6M | 101M | - | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 111M | 111M | 106M | 92.6M | 81.7M | 60.4M | 157M | 96.7M | 65.4M | 92.1M | 30.1M |
| Capital Expenditure | 4.44M | 2.98M | 77.3M | 153K | 1.88M | 4.45M | 2.70M | 3.26M | 64.7M | 330M | 58.8M |
| Free Cash Flow | - | 107M | 28.1M | 92.4M | 79.8M | 56.0M | 155M | 93.5M | 654K | -237M | -28.7M |
| Ratios | |||||||||||
| ROE | 18.0% | 30.0% | 16.4% | 14.9% | 13.6% | 10.5% | 19.7% | 17.6% | 9.0% | 9.6% | 8.4% |
| ROA | 11.1% | 22.4% | 12.6% | 11.5% | 10.7% | 8.3% | 16.3% | 13.4% | 7.4% | 7.7% | 6.2% |
| Net Profit Margin | 13.7% | 27.0% | 15.5% | 14.9% | 15.2% | 13.3% | 16.4% | 17.6% | 13.6% | 14.2% | 12.4% |
| Debt to Equity | - | - | - | - | 0.11x | 0.08x | 0.03x | 0.16x | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Li Kang Biomedical Co Ltd dividends
- Dividend yield
- 6.35%
- Forward dividend
- 2.00 TWD
- Payout ratio
- 75.9%
- Ex-dividend date
- Jun 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 63.6M | 2.00 | 75.9% |
| 2024 | TWD 79.5M | 2.50 | 103.2% |
| 2023 | TWD 46.6M | 1.67 | 42.0% |
| 2022 | TWD 33.3M | 1.19 | 29.7% |
| 2021 | TWD 62.2M | 2.23 | 120.8% |
| 2020 | TWD 44.4M | 1.59 | 64.1% |
| 2019 | TWD 55.5M | 1.99 | 77.1% |
| 2018 | TWD 55.5M | 2.50 | 72.3% |
| 2017 | TWD 28.9M | 1.30 | 21.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1150:1000 on Jun 30, 2023.
Who owns Li Kang Biomedical Co Ltd
- Insiders 64.92%
- Institutions 0.00%
- Public & others 35.08%
- Shares outstanding 31.8M
- Free float 12.6M
Li Kang Biomedical Co Ltd company profile
- Company name
- Li Kang Biomedical Co Ltd
- Ticker
- 6242.TWO
- ISIN
- TW0006242001
- Exchange
- Taiwan OTC Exchange
- Sector
- Consumer Cyclical
- Industry
- Personal Care Products
- Fiscal year end
- December
- Address
- No. 29, Huangong Road, Tainan City, Taiwan, 710
- Phone
- 886 6 201 5859
- Website
- likangbio.com
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. produces and sells pharmaceuticals, beauty products, and health food. It offers Chinese and Western medicines, nutritional supplements, beauty and skincare products, and daily necessities products. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded in 1982 and is based in Tainan City, Taiwan.
Li Kang Biomedical Co Ltd management
2- Yu-Xiu ZhengChairman & Manager
- Li Yu LinAccounting Supervisor